NDAINJECTIONINJECTABLE
Approved
Nov 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ENLON-PLUS (atropine sulfate; edrophonium chloride) by Pharmobedient is muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Approved for older for: atropine is an anticholinergic agent indicated in adults, older for: cycloplegia () mydriasis () penalization of the healthy eye in the treatment of amblyopia () 1. First approved in 1991.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENLON-PLUS is an injectable combination of atropine sulfate (antimuscarinic agent) and edrophonium chloride indicated for cycloplegia, mydriasis, and amblyopia treatment in adults. Atropine blocks muscarinic cholinergic receptors to produce pupillary dilation and loss of accommodation, while edrophonium enhances acetylcholine activity. The product targets ophthalmic and diagnostic applications requiring rapid-onset anticholinergic effects.
LOE Approaching
With LOE approaching and minimal current spending visibility, brand teams will focus on lifecycle extension strategies and transition planning rather than growth initiatives.
Mechanism of Action
muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does…
Worked on ENLON-PLUS at Pharmobedient? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.